Jeff Barrett appointed CTTV's founding director
This article was originally published in Scrip
Dr Jeffrey Barrett has been appointed the founding director of the Centre for Therapeutic Target Validation (CTTV), a public-private partnership between GlaxoSmithKline, the European Bioinformatics Institute (EMBL-EBI) and the Wellcome Trust Sanger Institute (scripintelligence.com, 27 March 2014). Dr Barrett has been involved in the CTTV since its inception in 2014 and will begin his new role on 1 May 2015.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.